[{"id":"d584e751-e3f2-4908-bfb6-b7b21ee2e46f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595683","created_at":"2021-01-18T17:40:49.334Z","updated_at":"2025-02-25T16:08:08.537Z","phase":"Phase 2","brief_title":"Pembrolizumab and EDP1503 in Advanced Melanoma","source_id_and_acronym":"NCT03595683","lead_sponsor":"University of Chicago","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • EDP1503"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 10/02/2018","start_date":" 10/02/2018","primary_txt":" Primary completion: 11/02/2027","primary_completion_date":" 11/02/2027","study_txt":" Completion: 11/02/2027","study_completion_date":" 11/02/2027","last_update_posted":"2024-07-31"}]